Chikungunya Combo Rapid Test

Bacterial/ Viral

Report in 12Hrs

At Home

No Fasting Required

Details

Simultaneous detection of IgM and IgG antibodies to the Chikungunya virus

₹1,249₹1,670

25% OFF

Chikungunya Combo Rapid Test - Comprehensive Medical Guide

Why is it done?
- Test Purpose: The Chikungunya Combo Rapid Test detects antibodies (IgM and IgG) against the Chikungunya virus in blood serum or plasma. This test identifies both acute and past infections with the Chikungunya virus, a mosquito-borne alphavirus transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes.
- Primary Indications: Suspected Chikungunya virus infection presenting with fever, joint pain (arthralgia), and rash; Confirmation of acute Chikungunya infection in symptomatic patients; Epidemiological surveillance in endemic regions; Screening of blood donors in affected areas; Differential diagnosis in patients with fever and joint pain in tropical and subtropical regions.
- Typical Timing: Best performed within 3-5 days of symptom onset for IgM detection; Can be performed during acute febrile phase and early convalescent phase; IgG antibodies appear after 5-7 days and persist for years; Most useful during epidemics or in endemic regions when Chikungunya is suspected.
Normal Range
- Negative Result: No antibodies detected (IgM negative, IgG negative); Indicates absence of Chikungunya infection or infection occurred more than 12 months prior with complete antibody clearance (rare); Normal/expected finding in non-infected individuals.
- IgM Positive, IgG Negative: Indicates acute Chikungunya infection (current or recent within 2-3 weeks); Patient is likely in acute phase with active viral replication; Seropositivity typically appears 3-5 days after symptom onset and persists for 2-3 months.
- IgM Negative, IgG Positive: Indicates past/convalescent Chikungunya infection; Patient has developed immunity; Implies infection occurred weeks to months prior; IgG remains positive for years, providing long-term immunity.
- IgM Positive, IgG Positive: Indicates acute infection in convalescent phase; Transition between acute and past infection; Suggests infection occurring within 2-3 months; IgG levels are rising while IgM is declining.
- Units of Measurement: Rapid test results are reported qualitatively as Positive or Negative; Some quantitative tests may report antibody titers in International Units (IU/mL) or Index values; Combo tests typically use immunochromatographic methodology with visual interpretation of test bands.
Interpretation
- Acute Infection Interpretation: IgM positivity in appropriate clinical context (fever, arthralgia, rash) confirms acute Chikungunya infection; Timing of test is critical - early testing (first 3 days) may show false negatives; IgM positivity warrants clinical management and transmission precautions.
- Past Infection Interpretation: IgG-only positivity indicates previous infection with immunity development; Patient is unlikely to be reinfected; Does not require acute treatment but establishes epidemiological evidence of exposure.
- Factors Affecting Results: Timing of blood collection relative to symptom onset; Immunocompromised status may delay antibody production; Cross-reactivity with other alphaviruses (O'nyong'nyong, Ross River virus); Individual immune response variability; Presence of maternal antibodies in infants; Laboratory technical factors and test kit sensitivity/specificity.
- Clinical Significance Patterns: Strong positive results with high antibody titers indicate recent infection; Serial testing showing rising IgG titers confirms active immune response; Discordant results may necessitate confirmatory testing via ELISA or RT-PCR; In endemic regions, background IgG positivity can be high in general population.
Associated Organs
- Primary Organ Systems Involved: Musculoskeletal system (primary target) - joints, muscles, connective tissues; Integumentary system - skin manifestations and rash; Hematopoietic system - potential blood cell involvement; Nervous system - rare neurological complications; Cardiovascular system - in severe cases.
- Associated Medical Conditions: Acute febrile illness with high fever (up to 40°C); Polyarthralgia/polyarthritis affecting multiple joints; Maculopapular rash on trunk and extremities; Post-Chikungunya chronic arthritis persisting months to years; Myalgia and general malaise; Thrombocytopenia in severe cases; Hepatitis with elevated liver enzymes.
- Diseases Diagnosed/Monitored: Chikungunya virus infection; Acute febrile illness in tropical regions; Post-Chikungunya chronic arthritis syndrome; Differential diagnosis from dengue fever, Zika virus, O'nyong'nyong fever; Atypical presentations in immunocompromised patients; Chikungunya-related complications in specific populations.
- Potential Complications with Abnormal Results: Severe arthritis and joint deformities; Chronic pain syndrome lasting months to years; Secondary bacterial infections of skin lesions; Severe thrombocytopenia leading to hemorrhage; Neurological complications including Guillain-Barré syndrome; Myocarditis in severe cases; Complications in pregnant women affecting fetal development; Increased severity in elderly and immunocompromised patients.
Follow-up Tests
- Confirmatory Testing: ELISA (Enzyme-Linked Immunosorbent Assay) for quantitative IgM and IgG antibody titers; RT-PCR (Reverse Transcription-Polymerase Chain Reaction) for detection of viral RNA in acute phase; Virus isolation/culture in specialized laboratories; Neutralization assays for serological confirmation.
- Additional Investigations Based on Results: Complete Blood Count (CBC) for thrombocytopenia assessment; Liver Function Tests (LFTs) to evaluate hepatic involvement; Inflammatory markers (CRP, ESR) for inflammation assessment; Synovial fluid analysis if arthritis develops; Imaging studies (X-ray, MRI) for chronic arthritis evaluation; Dengue serology to exclude co-infection or differentiate from dengue.
- Monitoring Frequency: Acute phase: Daily to every 2-3 days if severe; Serial serology at 2-week intervals if epidemiological investigation needed; Chronic arthritis cases: Monthly to quarterly follow-up depending on severity; Blood donor screening: Every donation in endemic areas; Pregnant women: Enhanced monitoring throughout pregnancy.
- Complementary Related Tests: Dengue IgM/IgG testing for differentiation; Zika virus serology in endemic areas; O'nyong'nyong virus antibodies; General febrile panel including malaria parasites; Blood cultures if bacterial superinfection suspected; Joint imaging and rheumatological markers for chronic cases.
Fasting Required?
- Fasting Requirement: No
- Special Instructions: Fasting is not required for serum antibody testing; Food and fluid intake do not affect antibody detection; Test can be performed at any time of day.
- Medications to Avoid: No specific medications need to be avoided for this test; Antimalarial medications do not interfere with testing; NSAIDs used for symptom management do not affect results; Antibiotics do not affect antibody detection.
- Patient Preparation Requirements: Inform healthcare provider of symptom onset date for proper test interpretation; Document fever onset and duration; Report other symptoms including joint pain, rash, and myalgia; Disclose recent travel history to endemic regions; Mention any other concurrent illnesses or infections; Advise on proper timing of blood collection (ideally 3-5 days after symptom onset for acute cases); Blood sample collection requires venipuncture or finger prick depending on test type.

How our test process works!